The federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency under the U.S. Department of Defense. The contract was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order with a ceiling value of $8,576.28 and an ultimate completion date of October 17, 2024.
DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December 31, 2025. This IDC allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including both routine and specialized drugs, to support the diverse medical needs of military personnel and their dependents across various Department of Defense healthcare facilities. The contract for the NEXPLANON 68 MG IMPLANTS is issued under this larger IDC vehicle.
The contract does not have a set-aside designation. As a woman-owned small business, DMS Pharmaceutical Group leverages its status to secure direct awards for pharmaceutical Prime Vendor programs supporting military medical facilities globally.
Generated 12/25/24, 9:19 AM